Karen Fang

Docetaxel for Metastatic Cancer and Its Role in Combination Therapies for Advanced Prostate Cancer

M. Gleave, M. Bally, E. Wasan, 2005 .

QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outcomes in an orthotopic breast cancer model

K. Gelmon, S. Dedhar, M. Bally, 2009, Breast Cancer Research.

Modulation of cancer cell survival pathways using multivalent liposomal therapeutic antibody constructs

M. Bally, C. Tucker, G. Chikh, 2007, Molecular Cancer Therapeutics.

Nanocarriers as an Emerging Platform for Cancer Therapy

J. Karp, R. Langer, D. Peer, 2022 .